Literature DB >> 20068105

Glioma-associated cancer-initiating cells induce immunosuppression.

Jun Wei1, Jason Barr, Ling-Yuan Kong, Yongtao Wang, Adam Wu, Amit K Sharma, Joy Gumin, Verlene Henry, Howard Colman, Raymond Sawaya, Frederick F Lang, Amy B Heimberger.   

Abstract

PURPOSE: Glioblastoma multiforme is a lethal cancer that responds poorly to therapy. Glioblastoma multiforme cancer-initiating cells have been shown to mediate resistance to both chemotherapy and radiation; however, it is unknown to what extent these cells contribute to the profound immunosuppression in glioblastoma multiforme patients and if strategies that alter their differentiation state can reduce this immunosuppression. EXPERIMENTAL
DESIGN: We isolated a subpopulation of cells from glioblastoma multiforme that possessed the capacity for self-renewal, formed neurospheres in vitro, were capable of pluripotent differentiation, and could initiate tumors in vivo. The immune phenotype of these cells was characterized including the elaboration of immunosuppressive cytokines and chemokines by ELISA. Functional immunosuppressive properties were characterized based on the inhibition of T-cell proliferation and effector responses, triggering of T-cell apoptosis, and induction of FoxP3(+) regulatory T cells. On altering their differentiation state, the immunosuppressive phenotype and functional assays were reevaluated.
RESULTS: We found that the cancer-initiating cells markedly inhibited T-cell proliferation and activation, induced regulatory T cells, and triggered T-cell apoptosis that was mediated by B7-H1 and soluble Galectin-3. These immunosuppressive properties were diminished on altering the differentiation of the cancer-initiating cells.
CONCLUSION: Cancer-initiating cells contribute to tumor evasion of the immunosurveillance and approaches that alter the differentiation state may have immunotherapeutic potential.

Entities:  

Mesh:

Year:  2010        PMID: 20068105      PMCID: PMC2943842          DOI: 10.1158/1078-0432.CCR-09-1983

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  42 in total

1.  T-lymphocyte entry into the central nervous system.

Authors:  W F Hickey; B L Hsu; H Kimura
Journal:  J Neurosci Res       Date:  1991-02       Impact factor: 4.164

2.  Chemicals that modulate stem cell differentiation.

Authors:  Ki-Chul Hwang; Ji Young Kim; Woochul Chang; Dae-Sung Kim; Soyeon Lim; Sang-Moon Kang; Byeong-Wook Song; Hye-Yeong Ha; Yong Joon Huh; In-Geol Choi; Dong-Youn Hwang; Heesang Song; Yangsoo Jang; Namsik Chung; Sung-Hou Kim; Dong-Wook Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-14       Impact factor: 11.205

3.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression.

Authors:  German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2006

4.  Isolation of neural stem cells from the postnatal cerebellum.

Authors:  Audra Lee; Jessica D Kessler; Tracy-Ann Read; Constanze Kaiser; Denis Corbeil; Wieland B Huttner; Jane E Johnson; Robert J Wechsler-Reya
Journal:  Nat Neurosci       Date:  2005-05-22       Impact factor: 24.884

5.  Nitric-oxide-dependent systemic immunosuppression in animals with progressively growing malignant gliomas.

Authors:  P Hegardt; B Widegren; H O Sjögren
Journal:  Cell Immunol       Date:  2000-03-15       Impact factor: 4.868

6.  Human mesenchymal stem cells modulate allogeneic immune cell responses.

Authors:  Sudeepta Aggarwal; Mark F Pittenger
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

7.  Heterogeneity among human bone marrow-derived mesenchymal stem cells and neural progenitor cells.

Authors:  Wichard Vogel; Frank Grünebach; Conrad A Messam; Lothar Kanz; Wolfram Brugger; Hans-Jörg Bühring
Journal:  Haematologica       Date:  2003-02       Impact factor: 9.941

8.  HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells.

Authors:  Katarina Le Blanc; Charlotte Tammik; Kerstin Rosendahl; Eva Zetterberg; Olle Ringdén
Journal:  Exp Hematol       Date:  2003-10       Impact factor: 3.084

Review 9.  Tumor antigens in astrocytic gliomas.

Authors:  S N Kurpad; X G Zhao; C J Wikstrand; S K Batra; R E McLendon; D D Bigner
Journal:  Glia       Date:  1995-11       Impact factor: 7.452

10.  CD133 (Prominin) negative human neural stem cells are clonogenic and tripotent.

Authors:  Yirui Sun; Weiqing Kong; Anna Falk; Jin Hu; Liangfu Zhou; Steve Pollard; Austin Smith
Journal:  PLoS One       Date:  2009-05-11       Impact factor: 3.240

View more
  103 in total

1.  Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.

Authors:  Christine E Brown; Renate Starr; Brenda Aguilar; Andrew F Shami; Catalina Martinez; Massimo D'Apuzzo; Michael E Barish; Stephen J Forman; Michael C Jensen
Journal:  Clin Cancer Res       Date:  2012-03-08       Impact factor: 12.531

Review 2.  Microglial cell origin and phenotypes in health and disease.

Authors:  Kaoru Saijo; Christopher K Glass
Journal:  Nat Rev Immunol       Date:  2011-10-25       Impact factor: 53.106

Review 3.  Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

Authors:  Amy B Heimberger; John H Sampson
Journal:  Neuro Oncol       Date:  2010-12-10       Impact factor: 12.300

Review 4.  Vaccines targeting cancer stem cells: are they within reach?

Authors:  Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

5.  Therapeutic vaccination based on side population cells transduced by the granulocyte-macrophage colony-stimulating factor gene elicits potent antitumor immunity.

Authors:  C Sakamoto; H Kohara; H Inoue; M Narusawa; Y Ogawa; L Hirose-Yotsuya; S Miyamoto; Y Matsumura; K Yamada; A Takahashi; K Tani
Journal:  Cancer Gene Ther       Date:  2017-01-13       Impact factor: 5.987

6.  Association Between Prediagnostic Serum 25-Hydroxyvitamin D Concentration and Glioma.

Authors:  Victoria Zigmont; Amy Garrett; Jin Peng; Michal Seweryn; Grzegorz A Rempala; Randall Harris; Christopher Holloman; Thomas E Gundersen; Anders Ahlbom; Maria Feychting; Tom Borge Johannesen; Tom Kristian Grimsrud; Judith Schwartzbaum
Journal:  Nutr Cancer       Date:  2015-08-28       Impact factor: 2.900

7.  A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells.

Authors:  Fabian Wolpert; Isabel Tritschler; Alexander Steinle; Michael Weller; Günter Eisele
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

Review 8.  Peptide vaccines for the treatment of glioblastoma.

Authors:  Adam M Swartz; Kristen A Batich; Peter E Fecci; John H Sampson
Journal:  J Neurooncol       Date:  2014-12-10       Impact factor: 4.130

9.  Cancer stem cell hypothesis: a brief summary and two proposals.

Authors:  Shuhua Zheng; Longzuo Xin; Aihua Liang; Yuejun Fu
Journal:  Cytotechnology       Date:  2012-12-19       Impact factor: 2.058

10.  Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses.

Authors:  Jonathan B Mitchem; Donal J Brennan; Brett L Knolhoff; Brian A Belt; Yu Zhu; Dominic E Sanford; Larisa Belaygorod; Danielle Carpenter; Lynne Collins; David Piwnica-Worms; Stephen Hewitt; Girish Mallya Udupi; William M Gallagher; Craig Wegner; Brian L West; Andrea Wang-Gillam; Peter Goedegebuure; David C Linehan; David G DeNardo
Journal:  Cancer Res       Date:  2012-12-05       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.